Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. The company was launched by a $31 million Series A investment by Accelerator Life Science Partners in 2018 and was co-founded by world-class researchers at The University of Texas MD Anderson Cancer Center. The company endeavors to make life-changing medicines for the benefit of patients and their families suffering from serious CNS diseases. The company's offices are located in the Alexandria Center for Life Science, New York City's first and only premier life science campus.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/13/18 | $31,000,000 | Series A |
180 Degree Capital AbbVie Biotech Ventures Alexandria Real Estate Equities ARCH Venture Partners Eli Lilly and Company Innovate NY Fund Johnson & Johnson Development Corporation (JJDC) Partnership Fund for New York City Pfizer Strategic Investments Group Watson Fund WuXi Corporate Venture Fund | undisclosed |
